LEXINGTON, Mass., Nov. 28,
2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)
(Aldeyra), a biotechnology company devoted to development of
next-generation medicines to improve the lives of patients with
immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of
Aldeyra, will participate at Citi's 2018 Global Healthcare
Conference on Wednesday, December 5,
2018 at the Lotte New York Palace Hotel in New York, NY.
About Aldeyra
Therapeutics
Aldeyra Therapeutics is
developing next-generation medicines to improve the lives of
patients with immune-mediated diseases. Aldeyra's lead product
candidate, reproxalap, is a first-in-class treatment in late-stage
development for dry eye disease and other forms of ocular
inflammation. The company is also developing other product
candidates for autoimmune disease, post-transplant
lymphoproliferative disease, retinal inflammation, metabolic
disease, and cancer. None of Aldeyra's product candidates
have been approved for sale in the U.S. or elsewhere.
Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcmullin@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-participate-at-citis-2018-global-healthcare-conference-300756510.html
SOURCE Aldeyra Therapeutics, Inc.